Medicure Inc.

Cardiovascular-focused drug discovery company reports Q1 2006 financial results

Published in Cardiovascular Business Week, November 15th, 2005

Medicure Inc. (MCU), a cardiovascular drug discovery and development company, reported the results of operations for the 3-month period ended August 31, 2005. All amounts referenced herein are in Canadian dollars unless otherwise noted.

The quarter was highlighted by the company raising gross proceeds of $4,685,000 (US$397,570) through a private placement. At August 31, 2005 the company had cash and cash equivalents totaling $7,573,000 (US$6,450,325) as compared to $7,591,000 (US$6,448,626) as at May 31, 2005. The cash position is sufficient to advance the company's lead products, MC-1 and MC-4232, up to pivotal phase 3 studies.

Research and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2005-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry